Prevention and Treatment of Regimen-Related Mucosal Toxicity
- By Joanne M. Bowen1
-
View Affiliations Hide Affiliations1 Department of Medical Oncology, Royal Adelaide Hospital, and School of Medicine, University of Adelaide, Adelaide, South Australia, 5000, Australia
- Source: Frontiers in Anti-Cancer Drug Discovery: Volume 1 , pp 588-600
- Publication Date: December 2010
- Language: English
Prevention and Treatment of Regimen-Related Mucosal Toxicity, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781608051618/chapter-26-1.gif
Current standard treatments for cancer are associated with major doselimiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and anti-inflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however, rational targeting of intervention strategies to critical mechanisms will lead to further progress.
-
From This Site
/content/books/9781608051618.chapter-26dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
